Psychedelic medicine biotechnology company developing psychedelic-inspired medicine and therapies to treat addiction and mental illness MindMed Inc. (NASDAQ: MNMD) (NEO: MMED) has announced some transitions among its managerial positions.
The company’s chief technology officer, Bradford Cross, has transitioned from his position. In addition the company’s chief science officer, Don Gehlert, will also be transitioning from his position however he will continue serving as a Senior Scientific Advisor.
MindMed’s director and chief executive officer, Robert Barrow, thanks Brandford Cross for his enormous contribution to the company further wishing him the best in what he decides to engage in after leaving the company.
“On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors. We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under the leadership of MindMed Chief Medical Officer, Dr. Daniel Karlin. We enter 2022 well positioned both financially and strategically to continue on our mission to transform mental health treatment,” said the CEO.
The CEO also acknowledged the transitioning of Don Gehlert, whom he said will continue to serve a very important role for the company. “Don has been and will continue to be an integral part of our organization. While this represents a change in his title, our entire team will continue to work closely with Don and benefit from his incredible breadth of experience in developing innovative CNS therapeutics,” added the CEO.
